Osteonecrosis in protease inhibitor-treated patients.
The introduction of protease inhibitors has proven a watershed in human immunodeficiency virus infection therapy and has initiated an era of highly active antiretroviral therapy. However, the numerous data on the effectiveness of these therapeutic regimens have been cited with an ever-growing number of communications concerning adverse reactions. In particular, the widescale use of protease inhibitors has underlined a series of events not evidenced in the controlled clinical studies that permitted the registration of these drugs. We are conducting a cohort multicenter study to evaluate the incidence of adverse events during treatment with protease inhibitors. To date, 4 cases of bilateral osteonecrosis of the femoral head have been reported out of 1073 person-years. While the pathogenesis of this event is unclear, it may be a long-term complication of protease inhibitor treatment.
Bonfanti
P
P
I Department of Infectious Diseases and Allergy, Luigi Sacco Hospital, Milan, Italy.
Grabbuti
A
A
Carradori
S
S
Pusterla
L
L
Parrazini
F
F
Landonio
S
S
Quirino
T
T
D000328:Adult; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D008297:Male; D010020:Osteonecrosis / Q000139:chemically induced* / Q000453:epidemiology; D018570:Risk Assessment
D017320:HIV Protease Inhibitors